SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump For President

The Trump Crypto coin is trending as the community discusses its volatile price action and potential connection to political events, as well as possible connections to the Trump family. Community members are actively debating its long-term potential amidst broader discussions about memecoins and the crypto market. Some traders are expressing concerns over recent performance.

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is trending, with community members highlighting its potential for a breakout and low market cap. Traders are closely watching key levels and volume, noting positive chart structure and momentum, while also pointing to its availability on Phantom Wallet and association with other meme coins.

WorldFinancial

$WLFI is trending amidst community discussions around its association with $TRUMP and potential for 'generational wealth.' Some speculate on its regulatory compliance benefits and tokenization of real-world assets, while others express skepticism, citing centralization and lack of utility; the community is split between bullish excitement and bearish concern.

Just a dead guy

$DEADGUY is trending as the community promotes the coin and shares the contract address. Social media mentions are up as the coin gains holders and climbs in wallet rankings. Discussion includes speculation that $DEADGUY could surpass other similar coins.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid rumors of a potential acquisition by Novartis, which has sparked significant discussion among investors. The community is focused on the potential buyout price and what this may mean for other companies in the RNA therapeutics space. Community members point to strong financials and potential for continued growth and have fueled speculation around other potential suitors.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss potential breakouts and accumulation zones for related tokens like $SMAS and $WAGMI. Some traders are watching key resistance levels, while others express optimism about Solana's future growth and potential ETF approval. There's also discussion around meme coins built on Solana, like $UPDOG and $SOLYCAT.

Columbus Circle Capital Corp. I operates as a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which refer to throughout this prospectus as initial business combination. The company was founded in June 2024 and is headquartered in New York, NY.

Columbus Circle Capital Corp I - Ordinary Shares - Class A

Columbus Circle Capital Corp I ($BRR) is trending as the community discusses recent board member additions, including Eric Jackson, with speculation that Mike Alfred may join soon. Chatter suggests a potential short-term swing due to low risk near the NAV floor and excitement around cheap options. Some are comparing the potential of $BRR options to past option surges.

AlienBase

AlienBase ($ALB) is trending as chatter increases around its potential Coinbase listing and a recent video highlighting the token. Community members are actively discussing the token's low market cap compared to competitors and speculating on future price appreciation. The project is also getting noticed for its working product and the belief that it will outperform other base coins.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction in the project's long-term potential within the Solana ecosystem. Discussions highlight its reflexive liquidity model and its potential for significant growth, with many seeing it as more than just a meme coin. Some users are suggesting now is an opportune time to invest.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences ($SGMT) is trending due to positive Phase 3 trial data for its acne treatment, denifanstat, potentially offering a new Accutane alternative with fewer side effects. The community is buzzing about its market potential, especially in China, and speculating about a possible buyout from larger skincare companies. Some analysts see the stock as undervalued, citing its market cap and opportunities in both the acne and MASH markets.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IDXG Very respectable quarter given the PancraGen overhang.   Revenues are within 80% of what they were when PancraGen was around.   Cash flow positive and cash flow will dramatically increase after the October 1 debt is extinguished. 
 
The PancraGen delay undoubtedly saved the company in that PE gave up their preference and a good chunk of the (then) $12MM debt got paid while it was around. 
 
Waiting for the Q.  But with $3.3MM disclosed in July?   We&#39;re talking revenues of close to $40MM without Pancragen.   At 1.5 times revenues?  That&#39;s about $60MM.   27MM shares.  That&#39;s a bit over $2.   I think that&#39;s we&#39;re sold and that&#39;s where I think we&#39;re going.

William Crane

Cornholio

Dr. Evil

Ron Burgundy

StockTwits Web

Interpace Biosciences Inc

 Very respectable quarter given the PancraGen overhang.   Revenues are within 80% of what they were when PancraGen was around.   Cash flow positive and cash flow will dramatically increase after the October 1 debt is extinguished. 
 
The PancraGen delay undoubtedly saved the company in that PE gave up their preference and a good chunk of the (then) $12MM debt got paid while it was around. 
 
Waiting for the Q.  But with $3.3MM disclosed in July?   We're talking revenues of close to $40MM without Pancragen.   At 1.5 times revenues?  That's about $60MM.   27MM shares.  That's a bit over $2.   I think that's we're sold and that's where I think we're going.